nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—Multiple sclerosis—Varenicline—nicotine dependence	0.081	0.0909	CcSEcCtD
Cevimeline—Costochondritis—Varenicline—nicotine dependence	0.0556	0.0624	CcSEcCtD
Cevimeline—Change of bowel habit—Varenicline—nicotine dependence	0.0506	0.0568	CcSEcCtD
Cevimeline—Myopia—Varenicline—nicotine dependence	0.0267	0.03	CcSEcCtD
Cevimeline—Pleurisy—Varenicline—nicotine dependence	0.0239	0.0268	CcSEcCtD
Cevimeline—Enterocolitis—Varenicline—nicotine dependence	0.021	0.0236	CcSEcCtD
Cevimeline—Peripheral ischaemia—Varenicline—nicotine dependence	0.016	0.0179	CcSEcCtD
Cevimeline—Respiratory tract congestion—Varenicline—nicotine dependence	0.016	0.0179	CcSEcCtD
Cevimeline—FMO1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0118	0.108	CbGpPWpGaD
Cevimeline—Urine abnormality—Varenicline—nicotine dependence	0.0105	0.0118	CcSEcCtD
Cevimeline—Sexual dysfunction—Varenicline—nicotine dependence	0.0104	0.0117	CcSEcCtD
Cevimeline—Osteoporosis—Varenicline—nicotine dependence	0.0104	0.0117	CcSEcCtD
Cevimeline—Gastric ulcer—Varenicline—nicotine dependence	0.01	0.0113	CcSEcCtD
Cevimeline—Urine analysis abnormal—Varenicline—nicotine dependence	0.00992	0.0111	CcSEcCtD
Cevimeline—Toothache—Varenicline—nicotine dependence	0.00958	0.0108	CcSEcCtD
Cevimeline—Vaginal discharge—Varenicline—nicotine dependence	0.00958	0.0108	CcSEcCtD
Cevimeline—Parosmia—Varenicline—nicotine dependence	0.00899	0.0101	CcSEcCtD
Cevimeline—Electrocardiogram abnormal—Varenicline—nicotine dependence	0.0089	0.00999	CcSEcCtD
Cevimeline—Intestinal obstruction—Varenicline—nicotine dependence	0.00855	0.00961	CcSEcCtD
Cevimeline—Paranoia—Varenicline—nicotine dependence	0.00855	0.00961	CcSEcCtD
Cevimeline—Menstrual disorder—Varenicline—nicotine dependence	0.00855	0.00961	CcSEcCtD
Cevimeline—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00841	0.0766	CbGpPWpGaD
Cevimeline—Delusion—Varenicline—nicotine dependence	0.00824	0.00925	CcSEcCtD
Cevimeline—Hyperlipidaemia—Varenicline—nicotine dependence	0.00809	0.00909	CcSEcCtD
Cevimeline—Mania—Varenicline—nicotine dependence	0.00802	0.009	CcSEcCtD
Cevimeline—Menorrhagia—Varenicline—nicotine dependence	0.00788	0.00885	CcSEcCtD
Cevimeline—Fungal infection—Varenicline—nicotine dependence	0.00755	0.00848	CcSEcCtD
Cevimeline—Gingivitis—Varenicline—nicotine dependence	0.00743	0.00834	CcSEcCtD
Cevimeline—Mydriasis—Varenicline—nicotine dependence	0.00731	0.00821	CcSEcCtD
Cevimeline—Nephrolithiasis—Varenicline—nicotine dependence	0.00725	0.00815	CcSEcCtD
Cevimeline—Glycosuria—Varenicline—nicotine dependence	0.0072	0.00808	CcSEcCtD
Cevimeline—Dysphonia—Varenicline—nicotine dependence	0.00709	0.00796	CcSEcCtD
Cevimeline—Endocrine disorder—Varenicline—nicotine dependence	0.00703	0.0079	CcSEcCtD
Cevimeline—FMO1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00664	0.0606	CbGpPWpGaD
Cevimeline—Aggression—Varenicline—nicotine dependence	0.00664	0.00745	CcSEcCtD
Cevimeline—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00656	0.0598	CbGpPWpGaD
Cevimeline—Viral infection—Varenicline—nicotine dependence	0.00645	0.00725	CcSEcCtD
Cevimeline—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.00645	0.00725	CcSEcCtD
Cevimeline—Thinking abnormal—Varenicline—nicotine dependence	0.00637	0.00715	CcSEcCtD
Cevimeline—Nocturia—Varenicline—nicotine dependence	0.00629	0.00706	CcSEcCtD
Cevimeline—FMO1—Biological oxidations—CYP2A7—nicotine dependence	0.00626	0.0571	CbGpPWpGaD
Cevimeline—Leukocytosis—Varenicline—nicotine dependence	0.0062	0.00697	CcSEcCtD
Cevimeline—FMO1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00618	0.0563	CbGpPWpGaD
Cevimeline—Coordination abnormal—Varenicline—nicotine dependence	0.00594	0.00667	CcSEcCtD
Cevimeline—Pulmonary embolism—Varenicline—nicotine dependence	0.00583	0.00655	CcSEcCtD
Cevimeline—Eructation—Varenicline—nicotine dependence	0.00573	0.00643	CcSEcCtD
Cevimeline—Hyperkalaemia—Varenicline—nicotine dependence	0.00573	0.00643	CcSEcCtD
Cevimeline—Influenza like illness—Varenicline—nicotine dependence	0.00566	0.00636	CcSEcCtD
Cevimeline—Salivary hypersecretion—Varenicline—nicotine dependence	0.00566	0.00636	CcSEcCtD
Cevimeline—Nightmare—Varenicline—nicotine dependence	0.00563	0.00632	CcSEcCtD
Cevimeline—Oesophagitis—Varenicline—nicotine dependence	0.00533	0.00598	CcSEcCtD
Cevimeline—Urine output increased—Varenicline—nicotine dependence	0.00527	0.00592	CcSEcCtD
Cevimeline—Mouth ulceration—Varenicline—nicotine dependence	0.00527	0.00592	CcSEcCtD
Cevimeline—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00521	0.0475	CbGpPWpGaD
Cevimeline—Hypertonia—Varenicline—nicotine dependence	0.00511	0.00574	CcSEcCtD
Cevimeline—Mental disability—Varenicline—nicotine dependence	0.00506	0.00568	CcSEcCtD
Cevimeline—Lymphadenopathy—Varenicline—nicotine dependence	0.00496	0.00557	CcSEcCtD
Cevimeline—Diabetes mellitus—Varenicline—nicotine dependence	0.00487	0.00547	CcSEcCtD
Cevimeline—Polyuria—Varenicline—nicotine dependence	0.00482	0.00541	CcSEcCtD
Cevimeline—Deafness—Varenicline—nicotine dependence	0.00473	0.00531	CcSEcCtD
Cevimeline—Eczema—Varenicline—nicotine dependence	0.00471	0.00529	CcSEcCtD
Cevimeline—Eye pain—Varenicline—nicotine dependence	0.00469	0.00527	CcSEcCtD
Cevimeline—Injury—Varenicline—nicotine dependence	0.0046	0.00517	CcSEcCtD
Cevimeline—Hot flush—Varenicline—nicotine dependence	0.00452	0.00508	CcSEcCtD
Cevimeline—Increased appetite—Varenicline—nicotine dependence	0.0045	0.00506	CcSEcCtD
Cevimeline—Amnesia—Varenicline—nicotine dependence	0.0045	0.00506	CcSEcCtD
Cevimeline—Menopausal symptoms—Varenicline—nicotine dependence	0.00449	0.00504	CcSEcCtD
Cevimeline—Thirst—Varenicline—nicotine dependence	0.00445	0.00499	CcSEcCtD
Cevimeline—Arthritis—Varenicline—nicotine dependence	0.00435	0.00489	CcSEcCtD
Cevimeline—Hypoglycaemia—Varenicline—nicotine dependence	0.00434	0.00487	CcSEcCtD
Cevimeline—Osteoarthritis—Varenicline—nicotine dependence	0.00423	0.00475	CcSEcCtD
Cevimeline—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00423	0.00475	CcSEcCtD
Cevimeline—Affect lability—Varenicline—nicotine dependence	0.00417	0.00468	CcSEcCtD
Cevimeline—Migraine—Varenicline—nicotine dependence	0.00417	0.00468	CcSEcCtD
Cevimeline—Urinary retention—Varenicline—nicotine dependence	0.00402	0.00452	CcSEcCtD
Cevimeline—Mood swings—Varenicline—nicotine dependence	0.00401	0.0045	CcSEcCtD
Cevimeline—Dry skin—Varenicline—nicotine dependence	0.00388	0.00436	CcSEcCtD
Cevimeline—Hypokalaemia—Varenicline—nicotine dependence	0.00385	0.00433	CcSEcCtD
Cevimeline—Gastritis—Varenicline—nicotine dependence	0.00375	0.00421	CcSEcCtD
Cevimeline—Abdominal distension—Varenicline—nicotine dependence	0.00368	0.00414	CcSEcCtD
Cevimeline—Asthma—Varenicline—nicotine dependence	0.00366	0.00411	CcSEcCtD
Cevimeline—Dysphagia—Varenicline—nicotine dependence	0.00366	0.00411	CcSEcCtD
Cevimeline—Angina pectoris—Varenicline—nicotine dependence	0.00356	0.004	CcSEcCtD
Cevimeline—Bronchitis—Varenicline—nicotine dependence	0.00352	0.00395	CcSEcCtD
Cevimeline—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00341	0.0311	CbGpPWpGaD
Cevimeline—Pollakiuria—Varenicline—nicotine dependence	0.00338	0.0038	CcSEcCtD
Cevimeline—Erectile dysfunction—Varenicline—nicotine dependence	0.00337	0.00378	CcSEcCtD
Cevimeline—Photosensitivity reaction—Varenicline—nicotine dependence	0.00334	0.00375	CcSEcCtD
Cevimeline—Weight increased—Varenicline—nicotine dependence	0.00333	0.00374	CcSEcCtD
Cevimeline—Hyperglycaemia—Varenicline—nicotine dependence	0.0033	0.00371	CcSEcCtD
Cevimeline—Depression—Varenicline—nicotine dependence	0.00325	0.00365	CcSEcCtD
Cevimeline—Acute coronary syndrome—Varenicline—nicotine dependence	0.00322	0.00361	CcSEcCtD
Cevimeline—Myocardial infarction—Varenicline—nicotine dependence	0.0032	0.00359	CcSEcCtD
Cevimeline—Stomatitis—Varenicline—nicotine dependence	0.00318	0.00357	CcSEcCtD
Cevimeline—Conjunctivitis—Varenicline—nicotine dependence	0.00317	0.00356	CcSEcCtD
Cevimeline—Epistaxis—Varenicline—nicotine dependence	0.00308	0.00346	CcSEcCtD
Cevimeline—Sinusitis—Varenicline—nicotine dependence	0.00306	0.00344	CcSEcCtD
Cevimeline—Hypoaesthesia—Varenicline—nicotine dependence	0.00291	0.00327	CcSEcCtD
Cevimeline—Hallucination—Varenicline—nicotine dependence	0.00291	0.00327	CcSEcCtD
Cevimeline—Oedema peripheral—Varenicline—nicotine dependence	0.00288	0.00324	CcSEcCtD
Cevimeline—Urethral disorder—Varenicline—nicotine dependence	0.00287	0.00322	CcSEcCtD
Cevimeline—Visual impairment—Varenicline—nicotine dependence	0.00282	0.00317	CcSEcCtD
Cevimeline—CHRM1—Monoamine GPCRs—DRD2—nicotine dependence	0.00277	0.0253	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—DRD2—nicotine dependence	0.00276	0.0252	CbGpPWpGaD
Cevimeline—Eye disorder—Varenicline—nicotine dependence	0.00274	0.00307	CcSEcCtD
Cevimeline—Tinnitus—Varenicline—nicotine dependence	0.00273	0.00307	CcSEcCtD
Cevimeline—Cardiac disorder—Varenicline—nicotine dependence	0.00272	0.00305	CcSEcCtD
Cevimeline—Angiopathy—Varenicline—nicotine dependence	0.00266	0.00298	CcSEcCtD
Cevimeline—Chills—Varenicline—nicotine dependence	0.00263	0.00295	CcSEcCtD
Cevimeline—Arrhythmia—Varenicline—nicotine dependence	0.00262	0.00294	CcSEcCtD
Cevimeline—Malnutrition—Varenicline—nicotine dependence	0.00255	0.00286	CcSEcCtD
Cevimeline—Flatulence—Varenicline—nicotine dependence	0.00251	0.00282	CcSEcCtD
Cevimeline—Dysgeusia—Varenicline—nicotine dependence	0.0025	0.0028	CcSEcCtD
Cevimeline—Back pain—Varenicline—nicotine dependence	0.00247	0.00277	CcSEcCtD
Cevimeline—Muscle spasms—Varenicline—nicotine dependence	0.00245	0.00275	CcSEcCtD
Cevimeline—Tremor—Varenicline—nicotine dependence	0.00239	0.00268	CcSEcCtD
Cevimeline—Ill-defined disorder—Varenicline—nicotine dependence	0.00236	0.00266	CcSEcCtD
Cevimeline—Anaemia—Varenicline—nicotine dependence	0.00236	0.00265	CcSEcCtD
Cevimeline—Agitation—Varenicline—nicotine dependence	0.00234	0.00263	CcSEcCtD
Cevimeline—CHRM1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00233	0.0212	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00232	0.0212	CbGpPWpGaD
Cevimeline—Malaise—Varenicline—nicotine dependence	0.0023	0.00258	CcSEcCtD
Cevimeline—Vertigo—Varenicline—nicotine dependence	0.00229	0.00257	CcSEcCtD
Cevimeline—Syncope—Varenicline—nicotine dependence	0.00229	0.00257	CcSEcCtD
Cevimeline—Palpitations—Varenicline—nicotine dependence	0.00225	0.00253	CcSEcCtD
Cevimeline—Loss of consciousness—Varenicline—nicotine dependence	0.00224	0.00252	CcSEcCtD
Cevimeline—Cough—Varenicline—nicotine dependence	0.00222	0.0025	CcSEcCtD
Cevimeline—Convulsion—Varenicline—nicotine dependence	0.00221	0.00248	CcSEcCtD
Cevimeline—Hypertension—Varenicline—nicotine dependence	0.0022	0.00247	CcSEcCtD
Cevimeline—Chest pain—Varenicline—nicotine dependence	0.00217	0.00244	CcSEcCtD
Cevimeline—Myalgia—Varenicline—nicotine dependence	0.00217	0.00244	CcSEcCtD
Cevimeline—Arthralgia—Varenicline—nicotine dependence	0.00217	0.00244	CcSEcCtD
Cevimeline—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00216	0.0197	CbGpPWpGaD
Cevimeline—Anxiety—Varenicline—nicotine dependence	0.00216	0.00243	CcSEcCtD
Cevimeline—Discomfort—Varenicline—nicotine dependence	0.00214	0.00241	CcSEcCtD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00214	0.0195	CbGpPWpGaD
Cevimeline—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00214	0.0195	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00213	0.0194	CbGpPWpGaD
Cevimeline—Oedema—Varenicline—nicotine dependence	0.00208	0.00234	CcSEcCtD
Cevimeline—Infection—Varenicline—nicotine dependence	0.00207	0.00232	CcSEcCtD
Cevimeline—Shock—Varenicline—nicotine dependence	0.00205	0.0023	CcSEcCtD
Cevimeline—Nervous system disorder—Varenicline—nicotine dependence	0.00204	0.00229	CcSEcCtD
Cevimeline—Thrombocytopenia—Varenicline—nicotine dependence	0.00204	0.00229	CcSEcCtD
Cevimeline—Tachycardia—Varenicline—nicotine dependence	0.00203	0.00228	CcSEcCtD
Cevimeline—Skin disorder—Varenicline—nicotine dependence	0.00202	0.00227	CcSEcCtD
Cevimeline—Hyperhidrosis—Varenicline—nicotine dependence	0.00201	0.00226	CcSEcCtD
Cevimeline—Anorexia—Varenicline—nicotine dependence	0.00198	0.00223	CcSEcCtD
Cevimeline—Hypotension—Varenicline—nicotine dependence	0.00194	0.00218	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.0019	0.00213	CcSEcCtD
Cevimeline—Insomnia—Varenicline—nicotine dependence	0.00188	0.00211	CcSEcCtD
Cevimeline—Dyspnoea—Varenicline—nicotine dependence	0.00185	0.00208	CcSEcCtD
Cevimeline—Somnolence—Varenicline—nicotine dependence	0.00185	0.00208	CcSEcCtD
Cevimeline—Dyspepsia—Varenicline—nicotine dependence	0.00183	0.00206	CcSEcCtD
Cevimeline—Decreased appetite—Varenicline—nicotine dependence	0.00181	0.00203	CcSEcCtD
Cevimeline—Fatigue—Varenicline—nicotine dependence	0.00179	0.00201	CcSEcCtD
Cevimeline—Pain—Varenicline—nicotine dependence	0.00178	0.002	CcSEcCtD
Cevimeline—Constipation—Varenicline—nicotine dependence	0.00178	0.002	CcSEcCtD
Cevimeline—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00175	0.016	CbGpPWpGaD
Cevimeline—Feeling abnormal—Varenicline—nicotine dependence	0.00171	0.00193	CcSEcCtD
Cevimeline—Gastrointestinal pain—Varenicline—nicotine dependence	0.0017	0.00191	CcSEcCtD
Cevimeline—Urticaria—Varenicline—nicotine dependence	0.00165	0.00186	CcSEcCtD
Cevimeline—Abdominal pain—Varenicline—nicotine dependence	0.00164	0.00185	CcSEcCtD
Cevimeline—Body temperature increased—Varenicline—nicotine dependence	0.00164	0.00185	CcSEcCtD
Cevimeline—Hypersensitivity—Varenicline—nicotine dependence	0.00153	0.00172	CcSEcCtD
Cevimeline—Asthenia—Varenicline—nicotine dependence	0.00149	0.00168	CcSEcCtD
Cevimeline—Pruritus—Varenicline—nicotine dependence	0.00147	0.00165	CcSEcCtD
Cevimeline—Diarrhoea—Varenicline—nicotine dependence	0.00142	0.0016	CcSEcCtD
Cevimeline—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00141	0.0129	CbGpPWpGaD
Cevimeline—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0014	0.0127	CbGpPWpGaD
Cevimeline—Dizziness—Varenicline—nicotine dependence	0.00138	0.00155	CcSEcCtD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00133	0.0121	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00132	0.0121	CbGpPWpGaD
Cevimeline—Vomiting—Varenicline—nicotine dependence	0.00132	0.00149	CcSEcCtD
Cevimeline—Rash—Varenicline—nicotine dependence	0.00131	0.00147	CcSEcCtD
Cevimeline—Dermatitis—Varenicline—nicotine dependence	0.00131	0.00147	CcSEcCtD
Cevimeline—Headache—Varenicline—nicotine dependence	0.0013	0.00146	CcSEcCtD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00127	0.0116	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00127	0.0116	CbGpPWpGaD
Cevimeline—Nausea—Varenicline—nicotine dependence	0.00124	0.00139	CcSEcCtD
Cevimeline—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00115	0.0105	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00114	0.0104	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—TAS2R16—nicotine dependence	0.00114	0.0104	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—CYP2A7—nicotine dependence	0.00107	0.00977	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000988	0.00901	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000932	0.00849	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000919	0.00838	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000883	0.00805	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000739	0.00674	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000737	0.00672	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—DRD2—nicotine dependence	0.000653	0.00595	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000647	0.0059	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000646	0.00589	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000645	0.00588	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000633	0.00577	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000631	0.00576	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000609	0.00555	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000601	0.00548	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000587	0.00535	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—TAS2R16—nicotine dependence	0.000585	0.00534	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000535	0.00487	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000533	0.00486	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—FGD1—nicotine dependence	0.000507	0.00463	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—FGD1—nicotine dependence	0.000506	0.00461	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—OPRM1—nicotine dependence	0.000482	0.0044	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—OPRM1—nicotine dependence	0.000481	0.00438	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—FGD1—nicotine dependence	0.000461	0.0042	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—FGD1—nicotine dependence	0.000459	0.00419	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000458	0.00418	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000456	0.00416	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—DRD2—nicotine dependence	0.000349	0.00318	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—DRD2—nicotine dependence	0.000348	0.00317	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TAS2R16—nicotine dependence	0.000347	0.00316	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TAS2R16—nicotine dependence	0.000346	0.00315	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000273	0.00249	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FGD1—nicotine dependence	0.000272	0.00248	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—OPRM1—nicotine dependence	0.000272	0.00248	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FGD1—nicotine dependence	0.000271	0.00247	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP2A7—nicotine dependence	0.000266	0.00243	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—OPRM1—nicotine dependence	0.000248	0.00226	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—OPRM1—nicotine dependence	0.000247	0.00225	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AKR1B10—nicotine dependence	0.00024	0.00219	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AKR1B10—nicotine dependence	0.00024	0.00219	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—DRD2—nicotine dependence	0.000197	0.0018	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—DRD2—nicotine dependence	0.000196	0.00179	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—DRD2—nicotine dependence	0.000179	0.00163	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—DRD2—nicotine dependence	0.000178	0.00163	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—WASF2—nicotine dependence	0.000169	0.00154	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—WASF2—nicotine dependence	0.000169	0.00154	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—WASF1—nicotine dependence	0.000162	0.00148	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—WASF1—nicotine dependence	0.000162	0.00148	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000159	0.00145	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—OPRM1—nicotine dependence	0.000146	0.00133	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—OPRM1—nicotine dependence	0.000146	0.00133	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—DRD2—nicotine dependence	0.000106	0.000964	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DRD2—nicotine dependence	0.000105	0.000961	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000104	0.00095	CbGpPWpGaD
